New MetrioPharm chair to steer MP1032 toward finish line
Zurich-based biotech MetrioPharm has appointed Stephan Rietiker as chair of its board of directors, following a unanimous vote by the newly formed board.
The company, focused on developing therapies for inflammatory and infectious diseases, said the new leadership aims to accelerate the clinical development and potential market entry of MP1032, its lead drug candidate.
Dr Rietiker, a physician by training, has held leadership roles at global firms including Roche (ROG: SIX), Boehringer Mannheim and LifeWatch. He described the company as being “in a promising position” and said the board’s goal would be to ensure “successful clinical development and swift commercialization” of MP1032.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze